Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Afatinib (Giotrif) for advanced or metastatic, squamous non-small cell lung cancer progressing on or after platinum-based chemotherapy. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives Non-small cell lung cancer is the most common type of lung cancer. It is often diagnosed late, once it has spread to other parts of the body and is difficult to treat.
Afatinib is a new drug for the treatment of non-small cell lung cancer given as a tablet. Some studies have suggested afatinib may be helpful for people whose first treatment has failed and whose disease has spread. Studies are currently ongoing to see how well afatinib works and how safe it is to use.
If afatinib is licensed for use in the UK, it could be a new treatment option for patients with non-small cell lung cancer who have not had success with their first treatment. Afatinib may improve survival and cause fewer side effects than current treatments. Indexing Status Subject indexing assigned by CRD MeSH Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Platinum; Quinazolines Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000436 Date abstract record published 04/03/2016 |